Secondary prevention and lipid lowering: Results and implications

Katherine M. Detre; Robert I. Levy; Sheryl F. Kelsey; Stephen E. Epstein; John F. Brensike; Eugene R. Passamani; John M. Richardson; Irving K. Loh; Neil J. Stone; Robert F. Aldrich; James W. Battaglini; Daniel J. Moriarty; Marian L. Fisher; Lawrence Friedman; William Friedewald

doi:10.1016/0002-8703(85)90227-3

Secondary prevention and lipid lowering: Results and implications

Katherine M. Detre^*, Robert I. Levy, Sheryl F. Kelsey, Stephen E. Epstein, John F. Brensike, Eugene R. Passamani, John M. Richardson, Irving K. Loh, Neil J. Stone, Robert F. Aldrich, James W. Battaglini, Daniel J. Moriarty, Marian L. Fisher, Lawrence Friedman, William Friedewald

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

In a secondary prevention trial conducted by the National Heart, Lung, and Blood Institute, the effect of lipid lowering by drug intervention on the progression of existing coronary artery disease (CAD) was evaluated in type II hyperlipidemic patients. This first randomized, secondary prevention trial compared the effect of cholestyramine and diet with that of placebo and diet in 143 patients over a 5-year period. End points evaluated were progression or regression of CAD, as demonstrated by angiographic changes compared with baseline angiograms. The cholestyramine-treated group demonstrated a significant reduction in total cholesterol and in low-density lipoprotein cholesterol (LDL) levels as compared with placebo, and an 8% increase in high-density lipoprotein cholesterol (HDL). A statistically significant result supporting the use of cholestyramine treatment was found in one category of CAD progression.

Original language	English (US)
Pages (from-to)	1123-1127
Number of pages	5
Journal	American heart journal
Volume	110
Issue number	5
DOIs	https://doi.org/10.1016/0002-8703(85)90227-3
State	Published - Nov 1985

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/0002-8703(85)90227-3

Cite this

Detre, K. M., Levy, R. I., Kelsey, S. F., Epstein, S. E., Brensike, J. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., Moriarty, D. J., Fisher, M. L., Friedman, L., & Friedewald, W. (1985). Secondary prevention and lipid lowering: Results and implications. American heart journal, 110(5), 1123-1127. https://doi.org/10.1016/0002-8703(85)90227-3

@article{fe985e543c1845bd9db06c3ab709fe41,

title = "Secondary prevention and lipid lowering: Results and implications",

abstract = "In a secondary prevention trial conducted by the National Heart, Lung, and Blood Institute, the effect of lipid lowering by drug intervention on the progression of existing coronary artery disease (CAD) was evaluated in type II hyperlipidemic patients. This first randomized, secondary prevention trial compared the effect of cholestyramine and diet with that of placebo and diet in 143 patients over a 5-year period. End points evaluated were progression or regression of CAD, as demonstrated by angiographic changes compared with baseline angiograms. The cholestyramine-treated group demonstrated a significant reduction in total cholesterol and in low-density lipoprotein cholesterol (LDL) levels as compared with placebo, and an 8% increase in high-density lipoprotein cholesterol (HDL). A statistically significant result supporting the use of cholestyramine treatment was found in one category of CAD progression.",

author = "Detre, {Katherine M.} and Levy, {Robert I.} and Kelsey, {Sheryl F.} and Epstein, {Stephen E.} and Brensike, {John F.} and Passamani, {Eugene R.} and Richardson, {John M.} and Loh, {Irving K.} and Stone, {Neil J.} and Aldrich, {Robert F.} and Battaglini, {James W.} and Moriarty, {Daniel J.} and Fisher, {Marian L.} and Lawrence Friedman and William Friedewald",

year = "1985",

month = nov,

doi = "10.1016/0002-8703(85)90227-3",

language = "English (US)",

volume = "110",

pages = "1123--1127",

journal = "American heart journal",

issn = "0002-8703",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Secondary prevention and lipid lowering

T2 - Results and implications

AU - Detre, Katherine M.

AU - Levy, Robert I.

AU - Kelsey, Sheryl F.

AU - Epstein, Stephen E.

AU - Brensike, John F.

AU - Passamani, Eugene R.

AU - Richardson, John M.

AU - Loh, Irving K.

AU - Stone, Neil J.

AU - Aldrich, Robert F.

AU - Battaglini, James W.

AU - Moriarty, Daniel J.

AU - Fisher, Marian L.

AU - Friedman, Lawrence

AU - Friedewald, William

PY - 1985/11

Y1 - 1985/11

N2 - In a secondary prevention trial conducted by the National Heart, Lung, and Blood Institute, the effect of lipid lowering by drug intervention on the progression of existing coronary artery disease (CAD) was evaluated in type II hyperlipidemic patients. This first randomized, secondary prevention trial compared the effect of cholestyramine and diet with that of placebo and diet in 143 patients over a 5-year period. End points evaluated were progression or regression of CAD, as demonstrated by angiographic changes compared with baseline angiograms. The cholestyramine-treated group demonstrated a significant reduction in total cholesterol and in low-density lipoprotein cholesterol (LDL) levels as compared with placebo, and an 8% increase in high-density lipoprotein cholesterol (HDL). A statistically significant result supporting the use of cholestyramine treatment was found in one category of CAD progression.

AB - In a secondary prevention trial conducted by the National Heart, Lung, and Blood Institute, the effect of lipid lowering by drug intervention on the progression of existing coronary artery disease (CAD) was evaluated in type II hyperlipidemic patients. This first randomized, secondary prevention trial compared the effect of cholestyramine and diet with that of placebo and diet in 143 patients over a 5-year period. End points evaluated were progression or regression of CAD, as demonstrated by angiographic changes compared with baseline angiograms. The cholestyramine-treated group demonstrated a significant reduction in total cholesterol and in low-density lipoprotein cholesterol (LDL) levels as compared with placebo, and an 8% increase in high-density lipoprotein cholesterol (HDL). A statistically significant result supporting the use of cholestyramine treatment was found in one category of CAD progression.

UR - http://www.scopus.com/inward/record.url?scp=0022201144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022201144&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(85)90227-3

DO - 10.1016/0002-8703(85)90227-3

M3 - Article

C2 - 3904378

AN - SCOPUS:0022201144

SN - 0002-8703

VL - 110

SP - 1123

EP - 1127

JO - American heart journal

JF - American heart journal

IS - 5

ER -

Secondary prevention and lipid lowering: Results and implications

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this